S&P 500   3,753.14 (-0.80%)
DOW   30,038.01 (-0.78%)
QQQ   280.47 (-0.54%)
AAPL   146.10 (-0.20%)
MSFT   247.02 (-0.87%)
META   136.99 (-1.43%)
GOOGL   101.22 (-0.21%)
AMZN   119.95 (-0.83%)
TSLA   238.54 (-0.94%)
NVDA   132.70 (+0.46%)
NIO   15.34 (-4.36%)
BABA   83.85 (-0.64%)
AMD   68.48 (+0.79%)
T   15.62 (-1.95%)
MU   53.56 (-2.14%)
CGC   3.01 (-1.95%)
F   12.37 (-1.12%)
GE   66.56 (-1.30%)
DIS   100.16 (-0.63%)
AMC   7.30 (-0.41%)
PYPL   94.45 (+0.66%)
PFE   43.42 (-1.59%)
NFLX   234.60 (-0.90%)
S&P 500   3,753.14 (-0.80%)
DOW   30,038.01 (-0.78%)
QQQ   280.47 (-0.54%)
AAPL   146.10 (-0.20%)
MSFT   247.02 (-0.87%)
META   136.99 (-1.43%)
GOOGL   101.22 (-0.21%)
AMZN   119.95 (-0.83%)
TSLA   238.54 (-0.94%)
NVDA   132.70 (+0.46%)
NIO   15.34 (-4.36%)
BABA   83.85 (-0.64%)
AMD   68.48 (+0.79%)
T   15.62 (-1.95%)
MU   53.56 (-2.14%)
CGC   3.01 (-1.95%)
F   12.37 (-1.12%)
GE   66.56 (-1.30%)
DIS   100.16 (-0.63%)
AMC   7.30 (-0.41%)
PYPL   94.45 (+0.66%)
PFE   43.42 (-1.59%)
NFLX   234.60 (-0.90%)
S&P 500   3,753.14 (-0.80%)
DOW   30,038.01 (-0.78%)
QQQ   280.47 (-0.54%)
AAPL   146.10 (-0.20%)
MSFT   247.02 (-0.87%)
META   136.99 (-1.43%)
GOOGL   101.22 (-0.21%)
AMZN   119.95 (-0.83%)
TSLA   238.54 (-0.94%)
NVDA   132.70 (+0.46%)
NIO   15.34 (-4.36%)
BABA   83.85 (-0.64%)
AMD   68.48 (+0.79%)
T   15.62 (-1.95%)
MU   53.56 (-2.14%)
CGC   3.01 (-1.95%)
F   12.37 (-1.12%)
GE   66.56 (-1.30%)
DIS   100.16 (-0.63%)
AMC   7.30 (-0.41%)
PYPL   94.45 (+0.66%)
PFE   43.42 (-1.59%)
NFLX   234.60 (-0.90%)
S&P 500   3,753.14 (-0.80%)
DOW   30,038.01 (-0.78%)
QQQ   280.47 (-0.54%)
AAPL   146.10 (-0.20%)
MSFT   247.02 (-0.87%)
META   136.99 (-1.43%)
GOOGL   101.22 (-0.21%)
AMZN   119.95 (-0.83%)
TSLA   238.54 (-0.94%)
NVDA   132.70 (+0.46%)
NIO   15.34 (-4.36%)
BABA   83.85 (-0.64%)
AMD   68.48 (+0.79%)
T   15.62 (-1.95%)
MU   53.56 (-2.14%)
CGC   3.01 (-1.95%)
F   12.37 (-1.12%)
GE   66.56 (-1.30%)
DIS   100.16 (-0.63%)
AMC   7.30 (-0.41%)
PYPL   94.45 (+0.66%)
PFE   43.42 (-1.59%)
NFLX   234.60 (-0.90%)
NASDAQ:ADPT

Adaptive Biotechnologies - ADPT Stock Forecast, Price & News

$7.94
+0.14 (+1.79%)
(As of 10/6/2022 10:15 AM ET)
Add
Compare
Today's Range
$7.76
$8.17
50-Day Range
$6.50
$12.67
52-Week Range
$5.95
$37.55
Volume
10,647 shs
Average Volume
1.11 million shs
Market Capitalization
$1.13 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$22.29

Adaptive Biotechnologies MarketRank™ Forecast

Analyst Rating
Hold
2.44 Rating Score
Upside/​Downside
180.7% Upside
$22.29 Price Target
Short Interest
Healthy
4.48% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.79
Upright™ Environmental Score
News Sentiment
0.75mentions of Adaptive Biotechnologies in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$200,451 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.58) to ($1.36) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.37 out of 5 stars

Medical Sector

288th out of 1,072 stocks

Biological Products, Except Diagnostic Industry

43rd out of 169 stocks

ADPT stock logo

About Adaptive Biotechnologies (NASDAQ:ADPT) Stock

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ, a clinical diagnostic product for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, as well as available as a CLIA-validated laboratory developed test for patients with other lymphoid cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Receive ADPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adaptive Biotechnologies and its competitors with MarketBeat's FREE daily newsletter.

ADPT Stock News Headlines

Adaptive Biotechnologies (NASDAQ:ADPT) Shares Up 11.9%
3 Cathie Wood Stocks for the Future
See More Headlines
Receive ADPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adaptive Biotechnologies and its competitors with MarketBeat's FREE daily newsletter.

ADPT Company Calendar

Last Earnings
8/03/2022
Today
10/06/2022
Next Earnings (Estimated)
11/02/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ADPT
Employees
858
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$22.29
High Stock Price Forecast
$50.00
Low Stock Price Forecast
$8.00
Forecasted Upside/Downside
+180.7%
Consensus Rating
Hold
Rating Score (0-4)
2.44
Research Coverage
9 Analysts

Profitability

Net Income
$-207,280,000.00
Net Margins
-145.37%
Pretax Margin
-145.44%

Debt

Sales & Book Value

Annual Sales
$154.34 million
Book Value
$4.28 per share

Miscellaneous

Free Float
136,872,000
Market Cap
$1.13 billion
Optionable
Not Optionable
Beta
1.02

Key Executives

  • Mr. Chad M. Robins M.B.AMr. Chad M. Robins M.B.A (Age 47)
    M.B.A., Co-Founder, CEO & Chairman
    Comp: $1.16M
  • Ms. Julie RubinsteinMs. Julie Rubinstein (Age 50)
    Pres
    Comp: $754.04k
  • Dr. Harlan S. Robins Ph.D. (Age 49)
    Co-Founder & Chief Scientific Officer
    Comp: $753.7k
  • Mr. Nitin Sood
    Chief Commercial Officer of MRD
  • Mr. Christopher Carlson Ph.D.
    Founder
  • Mr. Tycho W. Peterson
    Chief Financial Officer
  • Dr. Mark Adams Ph.D. (Age 55)
    Chief Operating Officer
  • Mr. Kyle Piskel (Age 38)
    Principal Accounting Officer
  • Yi Zhou
    Chief Technical Officer
  • Karina Calzadilla
    VP of Investor Relations













ADPT Stock - Frequently Asked Questions

Should I buy or sell Adaptive Biotechnologies stock right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Adaptive Biotechnologies in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ADPT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ADPT, but not buy additional shares or sell existing shares.
View ADPT analyst ratings
or view top-rated stocks.

What is Adaptive Biotechnologies' stock price forecast for 2022?

9 analysts have issued 1-year price objectives for Adaptive Biotechnologies' shares. Their ADPT share price forecasts range from $8.00 to $50.00. On average, they predict the company's stock price to reach $22.29 in the next year. This suggests a possible upside of 185.7% from the stock's current price.
View analysts price targets for ADPT
or view top-rated stocks among Wall Street analysts.

How have ADPT shares performed in 2022?

Adaptive Biotechnologies' stock was trading at $28.06 at the beginning of 2022. Since then, ADPT shares have decreased by 72.2% and is now trading at $7.80.
View the best growth stocks for 2022 here
.

When is Adaptive Biotechnologies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our ADPT earnings forecast
.

How were Adaptive Biotechnologies' earnings last quarter?

Adaptive Biotechnologies Co. (NASDAQ:ADPT) issued its quarterly earnings data on Wednesday, August, 3rd. The company reported ($0.37) EPS for the quarter, topping analysts' consensus estimates of ($0.40) by $0.03. The company earned $43.66 million during the quarter, compared to analysts' expectations of $43.30 million. Adaptive Biotechnologies had a negative net margin of 145.37% and a negative trailing twelve-month return on equity of 39.90%. During the same period in the prior year, the business earned ($0.35) earnings per share.

What guidance has Adaptive Biotechnologies issued on next quarter's earnings?

Adaptive Biotechnologies issued an update on its FY 2022 earnings guidance on Wednesday, August, 10th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $185.00 million-$195.00 million, compared to the consensus revenue estimate of $187.62 million.

What is Chad Robins' approval rating as Adaptive Biotechnologies' CEO?

51 employees have rated Adaptive Biotechnologies Chief Executive Officer Chad Robins on Glassdoor.com. Chad Robins has an approval rating of 92% among the company's employees. This puts Chad Robins in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Adaptive Biotechnologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adaptive Biotechnologies investors own include NVIDIA (NVDA), Alibaba Group (BABA), QUALCOMM (QCOM), Johnson & Johnson (JNJ), Advanced Micro Devices (AMD), CrowdStrike (CRWD), Home Depot (HD), Inovio Pharmaceuticals (INO), PayPal (PYPL) and Tesla (TSLA).

When did Adaptive Biotechnologies IPO?

(ADPT) raised $200 million in an initial public offering on Thursday, June 27th 2019. The company issued 12,500,000 shares at $15.00-$17.00 per share. Goldman Sachs, J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Cowen, Guggenheim Securities, William Blair and BTIG were co-managers.

What is Adaptive Biotechnologies' stock symbol?

Adaptive Biotechnologies trades on the NASDAQ under the ticker symbol "ADPT."

How do I buy shares of Adaptive Biotechnologies?

Shares of ADPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Adaptive Biotechnologies' stock price today?

One share of ADPT stock can currently be purchased for approximately $7.80.

How much money does Adaptive Biotechnologies make?

Adaptive Biotechnologies (NASDAQ:ADPT) has a market capitalization of $1.11 billion and generates $154.34 million in revenue each year. The company earns $-207,280,000.00 in net income (profit) each year or ($1.64) on an earnings per share basis.

How many employees does Adaptive Biotechnologies have?

The company employs 858 workers across the globe.

How can I contact Adaptive Biotechnologies?

Adaptive Biotechnologies' mailing address is 1551 EASTLAKE AVENUE EAST SUITE 200, SEATTLE WA, 98102. The official website for the company is www.constructionpartners.net. The company can be reached via phone at (206) 659-0067, via email at investors@adaptivebiotech.com, or via fax at 206-659-0667.

This page (NASDAQ:ADPT) was last updated on 10/6/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.